P

Provention Bio Inc
F:2VB

Watchlist Manager
Provention Bio Inc
F:2VB
Watchlist
Price: 21.6 EUR -0.46%
Market Cap: 2B EUR

EV/EBITDA
Enterprise Value to EBITDA

-16.2
Current
-15.1
Median
13.1
Industry
Lower than median
Lower than industry value

Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.

EV/EBITDA
-16.2
=
Enterprise Value
1.8B EUR
/
EBITDA
-126.9m USD
All Countries
Close
EBITDA Growth EV/EBITDA to Growth
US
P
Provention Bio Inc
F:2VB
Average EV/EBITDA: 437.3
Negative Multiple: -16.2
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
33.9
33%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.8
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.5
4%
2.9
UK
AstraZeneca PLC
LSE:AZN
108.1
10%
10.8
CH
Novartis AG
SIX:NOVN
11
6%
1.8
US
Merck & Co Inc
NYSE:MRK
9
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.1
2%
4.5
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.5
1%
7.5

EV/EBITDA Forward Multiples

Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBITDA
N/A
2-Years Forward
EV/EBITDA
N/A
3-Years Forward
EV/EBITDA
N/A